Coverage
-
January 20, 2023
The attorneys who represented investors in a class action against a New Jersey pharmaceutical company have won a $1.33 million fee award for the suit, which was based on allegedly broken promises the company made about how it would present new information about a drug.
4 other articles on this case.
View all »